David Kalergis

Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer

Retrieved on: 
Tuesday, September 8, 2020
David Kalergis

Dr. Cobuzzi is an accomplished pharmaceutical executive with significant and successful experience in the areas of drug development, business development and operational leadership across multiple therapeutic areas.

Key Points: 
  • Dr. Cobuzzi is an accomplished pharmaceutical executive with significant and successful experience in the areas of drug development, business development and operational leadership across multiple therapeutic areas.
  • "His deep leadership expertise and broad industry experience make him the ideal leader to drive product development and Company growth."
  • David G. Kalergis has retired as president and chief executive officer of the Company but will continue to serve as chairman of the board of the Company.
  • Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC

Retrieved on: 
Monday, July 27, 2020
Health, Clinical research, David Kalergis, Medical statistics, Design of experiments, Food and Drug Administration, Pharmaceutical industry, Clinical trial

This guidance suggests certain study design changes with regard to endpoints and statistical considerations that Diffusion believes will enhance the prospect of regulatory approvals upon program completion, should the clinical results be favorable.

Key Points: 
  • This guidance suggests certain study design changes with regard to endpoints and statistical considerations that Diffusion believes will enhance the prospect of regulatory approvals upon program completion, should the clinical results be favorable.
  • The Company previously announced expectations that the first patient would be enrolled in the Phase 1b study by the end of July.
  • Getting the clinical trial protocol right is imperative as it will support regulatory reviews and determinations, said David Kalergis, chief executive officer of Diffusion.
  • In 2019, the Company reported favorable safety data in a 19-patient dose-escalation run-in to its Phase 3 INTACT program using TSC to target inoperable GBM.

Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS

Retrieved on: 
Tuesday, May 5, 2020
Culture, Articles, Medical specialties, David Kalergis, Acute respiratory distress syndrome, TSC, Trans-cultural diffusion

Diffusion believes that TSCs novel oxygen-enhancing mechanism of action could provide an important new treatment option for this life-threatening condition.

Key Points: 
  • Diffusion believes that TSCs novel oxygen-enhancing mechanism of action could provide an important new treatment option for this life-threatening condition.
  • Clinical trial preparations at multiple potential sites are continuing as the Company awaits the FDAs expedited response.
  • This news of accelerated FDA review of the proposed clinical development plan for our lead compound TSC in a COVID-19 ARDS program is most welcome, said David Kalergis, chief executive officer of Diffusion.
  • Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the Coronavirus

Retrieved on: 
Tuesday, March 24, 2020
Health, David Kalergis, Coronaviridae, Clinical research, Clinical trial, Coronavirus, Articles

The coronavirus pandemic is affecting the conduct of clinical trials throughout the world, and the PHAST-TSC program is no exception, said Diffusions CEO, David Kalergis, JD/MBA.

Key Points: 
  • The coronavirus pandemic is affecting the conduct of clinical trials throughout the world, and the PHAST-TSC program is no exception, said Diffusions CEO, David Kalergis, JD/MBA.
  • We are following the FDAs recent guidelines for conducting clinical trials during this emergency, and are planning ways to make up lost time once the pandemic abates.
  • The Company is currently enrolling patients in its PHAST-TSC phase 2 clinical trial in acute stroke.
  • Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer

Retrieved on: 
Thursday, March 12, 2020
David Kalergis, Diffusion Pharmaceuticals, John L. Gainer

In recognition of the advancement of the TSC technology into the clinic, the Company has begun a search for a Chief Medical Officer as a replacement for the former Chief Science Officer position.

Key Points: 
  • In recognition of the advancement of the TSC technology into the clinic, the Company has begun a search for a Chief Medical Officer as a replacement for the former Chief Science Officer position.
  • He co-founded Diffusion Pharmaceuticals in 2001 with David Kalergis, the companys chairman and chief executive officer, serving on the board of directors.
  • He was named chief science officer in 2005 after his retirement as Professor Emeritus at the University of Virginia Department of Chemical Engineering, where he had served as a faculty member since 1966.
  • On behalf of everyone at Diffusion Pharmaceuticals, we want to wish Professor Gainer the best with his well-deserved retirement, said Mr. Kalergis.

Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC

Retrieved on: 
Friday, February 7, 2020
Health, Articles, Diffusion Pharmaceuticals, Radiation therapy, Brain tumor, RTT, David Kalergis, TSC, Crocetin, Patent, Pharmaceutical industry in China, Therapy

This patent relates to pharmaceutical compositions of trans sodium crocetinate (TSC) and a cyclodextrin for use in therapy.

Key Points: 
  • This patent relates to pharmaceutical compositions of trans sodium crocetinate (TSC) and a cyclodextrin for use in therapy.
  • Specifically claimed are TSC compositions are for use in conjunction with radiation or chemotherapy.
  • The intellectual property described under our newly-granted European patent is quite broad and provides strong protection for our lead compound TSC, said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals.
  • This patent has claims to TSC compositions for use in therapy generally and has claims to compositions for use in treating brain cancer.

Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors

Retrieved on: 
Friday, January 10, 2020
David Kalergis, Government procurement in the United States

Dr. Cobuzzi is an accomplished life sciences professional with 25 years of cross-functional leadership experience in the pharmaceutical and biotechnology industries.

Key Points: 
  • Dr. Cobuzzi is an accomplished life sciences professional with 25 years of cross-functional leadership experience in the pharmaceutical and biotechnology industries.
  • Over the course of his career, Dr. Cobuzzi has led multidisciplinary teams in executing over $6B in acquisitions, licenses and collaboration transactions.
  • We are fortunate to add a professional of Bobs stature to our board of directors, and welcome his experience and insight to Diffusion, said David Kalergis, chairman and chief executive officer of Diffusion.
  • Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.